SGPL1 and type 2 diabetes mellitus: Though further studies are needed to establish the role of SPL in long-term effects of FFAs in human beta-cells, particularly under hyperglycemic conditions, inhibition of SPL might represent a promising pharmacological tool for future T2DM therapeutic approaches to protect beta-cells under lipotoxic stress.